United States Chronic Kidney Disease. Market

Chronic Kidney Disease. Comprehensive Study by Diseases Type (Alport Syndrome, Amyloidosis, Cystinosis, Glomerulonephritis, Hemolytic Uremic Syndrome, Others), Treatment Type (Medications (ACE Inhibitors, Angiotensin II Receptor Blockers (ARBs), Diuretics, Calcium Channel Blockers, Beta-Blockers, Others), Dialysis, Kidney Transplantation, Others), Diagnostic Method (Blood Tests, Urine Tests, Imaging Tests, Biopsy Tests, Others), End User (Hospitals & Clinics, Ambulatory Surgery Centres (ASCs), Dialysis Centres, Others)

Chronic Kidney Disease. Market by XX Submarkets | Forecast Years 126-0  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
United States Chronic Kidney Disease. Market Overview:
Chronic kidney disease is a kind of kidney disease in which there is a steady loss of kidney function over a period of months or years. Early on there are usually no symptoms. Later, leg swelling, vomiting, feeling tired, loss of appetite, or confusion may develop. Complications may include high blood pressure, heart disease, bone disease, or anemia. There are some drugs & medications are available to control the symptoms & associated problems including ACE inhibitors, angiotensin-II receptor blockers, calcium channel blockers, beta blockers, erythropoiesis-stimulating agents (ESAs), diuretics, and others. Based on the distribution channel, the market has been segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

AttributesDetails
Study Period-
Base Year125
Forecast Period-
Historical Period-125
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility

Competitive Landscape:

Some of the key players profiled in the report are Abbott Laboratories, Amgen Inc., Bayer AG, AbbVie Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Merck & Co. Inc., GlaxoSmithKline plc, Siemens Healthineers, Pfizer Inc., Sysmex and Keryx Biopharmaceuticals, Inc.. Additionally, following companies can also be profiled that are part of our coverage like FibroGen (United States), Johnson & Johnson (United States) and Others. Considering Market by Diseases Type, the sub-segment i.e. Alport Syndrome will boost the Chronic Kidney Disease. market. Considering Market by Treatment Type, the sub-segment i.e. Medications (ACE Inhibitors, Angiotensin II Receptor Blockers (ARBs), Diuretics, Calcium Channel Blockers, Beta-Blockers, Others) will boost the Chronic Kidney Disease. market. Considering Market by Diagnostic Method, the sub-segment i.e. Blood Tests will boost the Chronic Kidney Disease. market. Considering Market by End User, the sub-segment i.e. Hospitals & Clinics will boost the Chronic Kidney Disease. market.

What Can be Explored with the Chronic Kidney Disease. Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the United States Chronic Kidney Disease. Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Chronic Kidney Disease.
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the United States Chronic Kidney Disease. market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Chronic Kidney Disease. market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Diseases Type
  • Alport Syndrome
  • Amyloidosis
  • Cystinosis
  • Glomerulonephritis
  • Hemolytic Uremic Syndrome
  • Others

By Treatment Type
  • Medications (ACE Inhibitors, Angiotensin II Receptor Blockers (ARBs), Diuretics, Calcium Channel Blockers, Beta-Blockers, Others)
  • Dialysis
  • Kidney Transplantation
  • Others

By Diagnostic Method
  • Blood Tests
  • Urine Tests
  • Imaging Tests
  • Biopsy Tests
  • Others

By End User
  • Hospitals & Clinics
  • Ambulatory Surgery Centres (ASCs)
  • Dialysis Centres
  • Others

By Regions
    • 1. Market Overview
      • 1.1. Introduction
      • 1.2. Scope/Objective of the Study
        • 1.2.1. Research Objective
    • 2. Executive Summary
      • 2.1. Introduction
    • 3. Market Factor Analysis
      • 3.1. Porters Five Forces
      • 3.2. Supply/Value Chain
      • 3.3. PESTEL analysis
      • 3.4. Market Entropy
      • 3.5. Patent/Trademark Analysis
    • 4. United States Chronic Kidney Disease., by Diseases Type, Treatment Type, Diagnostic Method and End User (value and price ) (120-125)
      • 4.1. Introduction
      • 4.2. United States Chronic Kidney Disease. (Value)
        • 4.2.1. United States Chronic Kidney Disease. by: Diseases Type (Value)
          • 4.2.1.1. Alport Syndrome
          • 4.2.1.2. Amyloidosis
          • 4.2.1.3. Cystinosis
          • 4.2.1.4. Glomerulonephritis
          • 4.2.1.5. Hemolytic Uremic Syndrome
          • 4.2.1.6. Others
        • 4.2.2. United States Chronic Kidney Disease. by: Treatment Type (Value)
          • 4.2.2.1. Medications (ACE Inhibitors, Angiotensin II Receptor Blockers (ARBs), Diuretics, Calcium Channel Blockers, Beta-Blockers, Others)
          • 4.2.2.2. Dialysis
          • 4.2.2.3. Kidney Transplantation
          • 4.2.2.4. Others
        • 4.2.3. United States Chronic Kidney Disease. by: Diagnostic Method (Value)
          • 4.2.3.1. Blood Tests
          • 4.2.3.2. Urine Tests
          • 4.2.3.3. Imaging Tests
          • 4.2.3.4. Biopsy Tests
          • 4.2.3.5. Others
        • 4.2.4. United States Chronic Kidney Disease. by: End User (Value)
          • 4.2.4.1. Hospitals & Clinics
          • 4.2.4.2. Ambulatory Surgery Centres (ASCs)
          • 4.2.4.3. Dialysis Centres
          • 4.2.4.4. Others
    • 5. Chronic Kidney Disease.: Manufacturers/Players Analysis
      • 5.1. Competitive Landscape
        • 5.1.1. Market Share Analysis
          • 5.1.1.1. Top 3
          • 5.1.1.2. Top 5
      • 5.2. Peer Group Analysis (125)
      • 5.3. BCG Matrix
      • 5.4. Company Profile
        • 5.4.1. Abbott Laboratories
          • 5.4.1.1. Business Overview
          • 5.4.1.2. Products/Services Offerings
          • 5.4.1.3. Financial Analysis
          • 5.4.1.4. SWOT Analysis
        • 5.4.2. Amgen Inc.
          • 5.4.2.1. Business Overview
          • 5.4.2.2. Products/Services Offerings
          • 5.4.2.3. Financial Analysis
          • 5.4.2.4. SWOT Analysis
        • 5.4.3. Bayer AG
          • 5.4.3.1. Business Overview
          • 5.4.3.2. Products/Services Offerings
          • 5.4.3.3. Financial Analysis
          • 5.4.3.4. SWOT Analysis
        • 5.4.4. AbbVie Inc.
          • 5.4.4.1. Business Overview
          • 5.4.4.2. Products/Services Offerings
          • 5.4.4.3. Financial Analysis
          • 5.4.4.4. SWOT Analysis
        • 5.4.5. Novartis AG
          • 5.4.5.1. Business Overview
          • 5.4.5.2. Products/Services Offerings
          • 5.4.5.3. Financial Analysis
          • 5.4.5.4. SWOT Analysis
        • 5.4.6. F. Hoffmann-La Roche Ltd.
          • 5.4.6.1. Business Overview
          • 5.4.6.2. Products/Services Offerings
          • 5.4.6.3. Financial Analysis
          • 5.4.6.4. SWOT Analysis
        • 5.4.7. Eli Lilly and Company
          • 5.4.7.1. Business Overview
          • 5.4.7.2. Products/Services Offerings
          • 5.4.7.3. Financial Analysis
          • 5.4.7.4. SWOT Analysis
        • 5.4.8. Merck & Co. Inc.
          • 5.4.8.1. Business Overview
          • 5.4.8.2. Products/Services Offerings
          • 5.4.8.3. Financial Analysis
          • 5.4.8.4. SWOT Analysis
        • 5.4.9. GlaxoSmithKline plc
          • 5.4.9.1. Business Overview
          • 5.4.9.2. Products/Services Offerings
          • 5.4.9.3. Financial Analysis
          • 5.4.9.4. SWOT Analysis
        • 5.4.10. Siemens Healthineers
          • 5.4.10.1. Business Overview
          • 5.4.10.2. Products/Services Offerings
          • 5.4.10.3. Financial Analysis
          • 5.4.10.4. SWOT Analysis
        • 5.4.11. Pfizer Inc.
          • 5.4.11.1. Business Overview
          • 5.4.11.2. Products/Services Offerings
          • 5.4.11.3. Financial Analysis
          • 5.4.11.4. SWOT Analysis
        • 5.4.12. Sysmex
          • 5.4.12.1. Business Overview
          • 5.4.12.2. Products/Services Offerings
          • 5.4.12.3. Financial Analysis
          • 5.4.12.4. SWOT Analysis
        • 5.4.13. Keryx Biopharmaceuticals, Inc.
          • 5.4.13.1. Business Overview
          • 5.4.13.2. Products/Services Offerings
          • 5.4.13.3. Financial Analysis
          • 5.4.13.4. SWOT Analysis
    • 6. United States Chronic Kidney Disease. Sale, by Diseases Type, Treatment Type, Diagnostic Method and End User (value and price ) (-5-0)
      • 6.1. Introduction
      • 6.2. United States Chronic Kidney Disease. (Value)
        • 6.2.1. United States Chronic Kidney Disease. by: Diseases Type (Value)
          • 6.2.1.1. Alport Syndrome
          • 6.2.1.2. Amyloidosis
          • 6.2.1.3. Cystinosis
          • 6.2.1.4. Glomerulonephritis
          • 6.2.1.5. Hemolytic Uremic Syndrome
          • 6.2.1.6. Others
        • 6.2.2. United States Chronic Kidney Disease. by: Treatment Type (Value)
          • 6.2.2.1. Medications (ACE Inhibitors, Angiotensin II Receptor Blockers (ARBs), Diuretics, Calcium Channel Blockers, Beta-Blockers, Others)
          • 6.2.2.2. Dialysis
          • 6.2.2.3. Kidney Transplantation
          • 6.2.2.4. Others
        • 6.2.3. United States Chronic Kidney Disease. by: Diagnostic Method (Value)
          • 6.2.3.1. Blood Tests
          • 6.2.3.2. Urine Tests
          • 6.2.3.3. Imaging Tests
          • 6.2.3.4. Biopsy Tests
          • 6.2.3.5. Others
        • 6.2.4. United States Chronic Kidney Disease. by: End User (Value)
          • 6.2.4.1. Hospitals & Clinics
          • 6.2.4.2. Ambulatory Surgery Centres (ASCs)
          • 6.2.4.3. Dialysis Centres
          • 6.2.4.4. Others
    • 7. Appendix
      • 7.1. Acronyms
    • 8. Methodology and Data Source
      • 8.1. Methodology/Research Approach
        • 8.1.1. Research Programs/Design
        • 8.1.2. Market Size Estimation
        • 8.1.3. Market Breakdown and Data Triangulation
      • 8.2. Data Source
        • 8.2.1. Secondary Sources
        • 8.2.2. Primary Sources
      • 8.3. Disclaimer
    List of Tables
    • Table 1. Chronic Kidney Disease.: by Diseases Type(USD Million)
    • Table 2. Chronic Kidney Disease.: by Treatment Type(USD Million)
    • Table 3. Chronic Kidney Disease.: by Diagnostic Method(USD Million)
    • Table 4. Chronic Kidney Disease.: by End User(USD Million)
    • Table 5. Company Basic Information, Sales Area and Its Competitors
    • Table 6. Company Basic Information, Sales Area and Its Competitors
    • Table 7. Company Basic Information, Sales Area and Its Competitors
    • Table 8. Company Basic Information, Sales Area and Its Competitors
    • Table 9. Company Basic Information, Sales Area and Its Competitors
    • Table 10. Company Basic Information, Sales Area and Its Competitors
    • Table 11. Company Basic Information, Sales Area and Its Competitors
    • Table 12. Company Basic Information, Sales Area and Its Competitors
    • Table 13. Company Basic Information, Sales Area and Its Competitors
    • Table 14. Company Basic Information, Sales Area and Its Competitors
    • Table 15. Company Basic Information, Sales Area and Its Competitors
    • Table 16. Company Basic Information, Sales Area and Its Competitors
    • Table 17. Company Basic Information, Sales Area and Its Competitors
    • Table 18. Chronic Kidney Disease.: by Diseases Type(USD Million)
    • Table 19. Chronic Kidney Disease.: by Treatment Type(USD Million)
    • Table 20. Chronic Kidney Disease.: by Diagnostic Method(USD Million)
    • Table 21. Chronic Kidney Disease.: by End User(USD Million)
    • Table 22. Research Programs/Design for This Report
    • Table 23. Key Data Information from Secondary Sources
    • Table 24. Key Data Information from Primary Sources
    List of Figures
    • Figure 1. Porters Five Forces
    • Figure 2. Supply/Value Chain
    • Figure 3. PESTEL analysis
    • Figure 4. United States Chronic Kidney Disease.: by Diseases Type USD Million (120-125)
    • Figure 5. United States Chronic Kidney Disease.: by Treatment Type USD Million (120-125)
    • Figure 6. United States Chronic Kidney Disease.: by Diagnostic Method USD Million (120-125)
    • Figure 7. United States Chronic Kidney Disease.: by End User USD Million (120-125)
    • Figure 8. United States Chronic Kidney Disease. share by Players 125 (%)
    • Figure 9. United States Chronic Kidney Disease. share by Players (Top 3) 125(%)
    • Figure 10. United States Chronic Kidney Disease. share by Players (Top 5) 125(%)
    • Figure 11. BCG Matrix for key Companies
    • Figure 12. Abbott Laboratories Revenue, Net Income and Gross profit
    • Figure 13. Abbott Laboratories Revenue: by Geography 125
    • Figure 14. Amgen Inc. Revenue, Net Income and Gross profit
    • Figure 15. Amgen Inc. Revenue: by Geography 125
    • Figure 16. Bayer AG Revenue, Net Income and Gross profit
    • Figure 17. Bayer AG Revenue: by Geography 125
    • Figure 18. AbbVie Inc. Revenue, Net Income and Gross profit
    • Figure 19. AbbVie Inc. Revenue: by Geography 125
    • Figure 20. Novartis AG Revenue, Net Income and Gross profit
    • Figure 21. Novartis AG Revenue: by Geography 125
    • Figure 22. F. Hoffmann-La Roche Ltd. Revenue, Net Income and Gross profit
    • Figure 23. F. Hoffmann-La Roche Ltd. Revenue: by Geography 125
    • Figure 24. Eli Lilly and Company Revenue, Net Income and Gross profit
    • Figure 25. Eli Lilly and Company Revenue: by Geography 125
    • Figure 26. Merck & Co. Inc. Revenue, Net Income and Gross profit
    • Figure 27. Merck & Co. Inc. Revenue: by Geography 125
    • Figure 28. GlaxoSmithKline plc Revenue, Net Income and Gross profit
    • Figure 29. GlaxoSmithKline plc Revenue: by Geography 125
    • Figure 30. Siemens Healthineers Revenue, Net Income and Gross profit
    • Figure 31. Siemens Healthineers Revenue: by Geography 125
    • Figure 32. Pfizer Inc. Revenue, Net Income and Gross profit
    • Figure 33. Pfizer Inc. Revenue: by Geography 125
    • Figure 34. Sysmex Revenue, Net Income and Gross profit
    • Figure 35. Sysmex Revenue: by Geography 125
    • Figure 36. Keryx Biopharmaceuticals, Inc. Revenue, Net Income and Gross profit
    • Figure 37. Keryx Biopharmaceuticals, Inc. Revenue: by Geography 125
    • Figure 38. United States Chronic Kidney Disease.: by Diseases Type USD Million (-5-0)
    • Figure 39. United States Chronic Kidney Disease.: by Treatment Type USD Million (-5-0)
    • Figure 40. United States Chronic Kidney Disease.: by Diagnostic Method USD Million (-5-0)
    • Figure 41. United States Chronic Kidney Disease.: by End User USD Million (-5-0)
    List of companies from research coverage that are profiled in the study
    • Abbott Laboratories
    • Amgen Inc.
    • Bayer AG
    • AbbVie Inc.
    • Novartis AG
    • F. Hoffmann-La Roche Ltd.
    • Eli Lilly and Company
    • Merck & Co. Inc.
    • GlaxoSmithKline plc
    • Siemens Healthineers
    • Pfizer Inc.
    • Sysmex
    • Keryx Biopharmaceuticals, Inc.
    Additional players considered in the study are as follows:
    FibroGen (United States) , Johnson & Johnson (United States) , Others
    Select User Access Type

    Key Highlights of Report


    Jan 2025 216 Pages 53 Tables Base Year: 125 Coverage: 15+ Companies; 18 Countries

    Request Sample Pages

    Budget constraints? Get in touch with us for special pricing


    Check Discount Now
    United States Chronic Kidney Disease. Market Quantitative research analysis
    United States Chronic Kidney Disease. Market Qualitative Industry Analysis
    DOWNLOAD SAMPLE PDF

    Talk to Our Experts

    Want to Customize Study?


    "We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

    Make an Enquiry Now

    Frequently Asked Questions (FAQ):

    Top performing companies in the United States Chronic Kidney Disease. market are Abbott Laboratories, Amgen Inc., Bayer AG, AbbVie Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Merck & Co. Inc., GlaxoSmithKline plc, Siemens Healthineers, Pfizer Inc., Sysmex and Keryx Biopharmaceuticals, Inc., to name a few.
    "" is seen as one of major influencing trends for Chronic Kidney Disease. Market during projected period 125-.

    Know More About United States Chronic Kidney Disease. Market Report?

    Have a Query? Click Here

    Other Related Reports

    Orphan Diseases Comprehensive Study by Disease Type (Oncology, Allergic and Immunologic Disorders, Cardiac and Vascular Conditions, Infectious Diseases, Neurologic Conditions, Skin and Soft Tissue Co...
    $ 3800
    Malocclusion Comprehensive Study by Type (Overcrowding, Spacing, Openbite, Overjet, Overbite, Underbite, Crossbite, Diastema, Impacted Tooth, Missing Tooth), Age Group (Children, Adults), Treatment T...
    $ 3800
    Membranous Nephropathy Comprehensive Study by Type (Primary Membranous Nephropathy (Idiopathic), Secondary Membranous Nephropathy), Age Group (Children, Adults), Treatment Type (Biologics, Pharmaceut...
    $ 3800
    Cardiovascular Application Comprehensive Study by Type (Diagnostic and Monitoring Devices, (Electrocardiogram, Holter Monitors, Event Monitors, Others), Interventional Devices, (Coronary Stents, Cath...
    $ 3800
    Ischemic stroke Comprehensive Study by Surgery Type (Carotid Endarterectomy, Angioplasty, Endovascular Mechanical Thrombectomy, Others), Treatment Type (Tissue Plasminogen Activator, Anticoagulant, A...
    $ 3800
    Depression Therapeutics- Comprehensive Study by Indication Type (Major depressive disorder (MDD), Bipolar disorder, Dysthymic disorder, Postpartum depression, Seasonal affective disorder (SAD), Preme...
    $ 3800